Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

Published byMaarit Väänänen Modified over 6 years ago

Similar presentations

Presentation on theme: "Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al."— Presentation transcript:

1 Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al. Am J Nephrol 2016;44: (DOI: / ) Table 1. Demographic and clinical characteristics of patients included in the post hoc analysis (n = 505)

2 Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al. Am J Nephrol 2016;44: (DOI: / ) Fig. 1. a–c Mean ± SD serum iPTH concentrations and changes versus baseline during the study period in each analysis population. NS= Not significant. * Indicates a statistically significant change from baseline (a) a  p = , b p = ; (b) a p = , b p = ; (c) p =

3 Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al. Am J Nephrol 2016;44: (DOI: / ) Fig. 1. a–c Mean ± SD serum iPTH concentrations and changes versus baseline during the study period in each analysis population. NS= Not significant. * Indicates a statistically significant change from baseline (a) a  p = , b p = ; (b) a p = , b p = ; (c) p =

4 Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al. Am J Nephrol 2016;44: (DOI: / ) Fig. 1. a–c Mean ± SD serum iPTH concentrations and changes versus baseline during the study period in each analysis population. NS= Not significant. * Indicates a statistically significant change from baseline (a) a  p = , b p = ; (b) a p = , b p = ; (c) p =

5 Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al. Am J Nephrol 2016;44: (DOI: / ) Table 2. Mixed-effects model analysis of change from baseline in iPTH concentrations at Overall Endpoint*: Population 1 (n = 187) vs. Population 2 (n = 250)

6 Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al. Am J Nephrol 2016;44: (DOI: / ) Table 3. Mixed-effects model analysis of change from baseline in iPTH concentrations at Overall Endpoint*: Population 1 (n = 187) vs. Population 3 (n = 68)

Download ppt "Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al."

Similar presentations

Fig. 4-1, p. 107. Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.
P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.
Fig. 11-1, p. 359. p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.
Table 6-1, p. 161. Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.

A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.
Effect of a Non-Calcium-Based Phosphate Binder on Fibroblast Growth Factor 23 in Chronic Kidney Disease Nephron Clin Pract 2013;123:61-66 - DOI:10.1159/000351811.

Effect of a Non-Calcium-Based Phosphate Binder on Fibroblast Growth Factor 23 in Chronic Kidney Disease Nephron Clin Pract 2013;123: DOI: /
Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.

Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.
high-flux dialysis membrane

high-flux dialysis membrane
The ECHO Observational Study

The ECHO Observational Study
Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients Am J Nephrol 2013;37:413-420 - DOI:10.1159/000349929 Fig. 1. Comparison.

Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients Am J Nephrol 2013;37: DOI: / Fig. 1. Comparison.
Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD Kidney Dis 2017;3:8-14 - DOI:10.1159/000477244 Fig. 1. Currently.

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD Kidney Dis 2017;3: DOI: / Fig. 1. Currently.
Effect of GnRH-agonist downregulation on serum AMH levels: a prospective cohort study with repeated measurements P. Drakopoulos1, A. van de Vijver1, J.

Effect of GnRH-agonist downregulation on serum AMH levels: a prospective cohort study with repeated measurements P. Drakopoulos1, A. van de Vijver1, J.
Locatelli et al. Am J Nephrol 2017;45:   (DOI: / )

Locatelli et al. Am J Nephrol 2017;45:   (DOI: / )
Thadhani et al. Am J Nephrol 2017;45:40-48  (DOI: / )

Thadhani et al. Am J Nephrol 2017;45:40-48  (DOI: / )
Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.
Fan et al. Am J Nephrol 2017;45:   (DOI: / )

Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Kuwabara et al. Am J Nephrol 2017;45:   (DOI: / )

Kuwabara et al. Am J Nephrol 2017;45:   (DOI: / )

Similar presentations

Ads by Google